Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
about
Tipping the balance both ways: drug resistance and virulence in Candida glabrataRegulatory roles of phosphorylation in model and pathogenic fungiResistance Mechanisms and Clinical Features of Fluconazole-Nonsusceptible Candida tropicalis Isolates Compared with Fluconazole-Less-Susceptible IsolatesCharacterization of a new clinical yeast species, Candida tunisiensis sp. nov., isolated from a strain collection from Tunisian hospitals.Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.Fungemia in a Spanish hospital: the role of Candida parapsilosis over a 15-year period.Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey.Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care centerPossible inhibitory molecular mechanism of farnesol on the development of fluconazole resistance in Candida albicans biofilm.Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by vitek 2, DNA sequencing analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillanClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study.Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.Accuracy of species-level identification of yeast isolates from blood cultures from 10 university hospitals in South Korea by use of the matrix-assisted laser desorption ionization-time of flight mass spectrometry-based Vitek MS systemSusceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpointsValidation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance programResistance patterns and clinical significance of Candida colonization and infection in combat-related injured patients from iraq and afghanistan.Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage.In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference methodPharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelAntifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infectionCryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilutionAssessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012Rapid Evaporative Ionisation Mass Spectrometry (REIMS) Provides Accurate Direct from Culture Species Identification within the Genus CandidaInvasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility.Repeated applications of photodynamic therapy on Candida glabrata biofilms formed in acrylic resin polymerized.Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.Echinocandin resistance in two Candida haemulonii isolates from pediatric patients.
P2860
Q26996199-51BBB867-531A-40CA-838B-B352D6F89316Q28087413-E86F8B89-F894-425F-ADA6-3EF9795C84EDQ28833536-D04905C4-4F2C-40DB-B8C9-D11972EBA042Q30573841-FD3600FE-F6F2-42BB-BD99-89D3D2043A85Q30797685-981B8279-F24C-4566-A8EF-8C3B2F89682CQ30808061-5C9B7007-EDFF-4FFC-BAF7-41FDC0AB9072Q30841261-D7628C34-E624-488C-ADE7-FE8436AA60CEQ34051921-81B5224C-32F3-4AA5-9FBA-1596B218BE1AQ34058322-1B6EDB57-BF4B-46EB-B4D1-C6255742AE05Q34079974-A21B495F-997D-41D6-8058-A4DC301AD386Q34165039-C70BD621-6ECE-4BCA-A11B-15D00AD69DA7Q34187320-8D076601-750D-4898-8D92-FCD7832EF1B0Q34372192-AB3BCF32-B76A-40E0-9456-5F6532FD4E4CQ34458142-EC901D4A-7B7C-4D3F-A51A-1603521A6CD3Q34505582-6137F472-3B8D-4359-A49E-CB0A763132B0Q34529179-6059A9C1-CA06-4E4F-ADD2-E207640E810CQ34586566-BF0790A3-DC34-429E-9D50-4A3BA75C4D70Q34737476-199F0297-1070-4667-B547-F3CE3E3588BDQ34778312-A132801C-59F8-441B-9289-6B6227B681D1Q34977249-B93BE633-1FD1-4922-84C2-AC34D2C24C74Q35067016-EF48B5C7-1FC6-479D-BFD8-C29F3999214CQ35072030-D9CF861B-BA81-4FE8-A5E0-21C1DCB06D10Q35112435-6863EC12-D184-4A51-8A6A-B0D12B7FB5E7Q35139558-917E313D-1EA1-47A9-BFA5-984378619F4BQ35487439-8A29784A-DD67-4692-8871-CAD0E766C159Q35598950-2172A433-67EC-4B4F-9555-7272A878CFEAQ35666627-1E68D86D-0C69-4E7F-9FCD-A0E90E390FFBQ35746090-1C57550D-1658-43CC-AE38-F3E466C993C8Q35867789-A268B06A-009E-4186-A96F-20880AA66769Q35941237-EC0B7418-45D0-4B48-817E-EDDA1D759EC3Q35941512-FC89C4C0-C649-42DF-A1A0-5072D84995C1Q36018713-45CDBC4E-86B9-4A59-BC39-F61A5C68762CQ36022956-259380BE-0309-498C-825F-5A13F3018627Q36171475-4FA34B72-560C-4A77-B1AB-59A151AA9537Q36172242-1B6CC2EB-7051-4FA8-B584-321694ED6BA0Q36191450-F559E2D1-C2BF-4879-AC5E-DAED22BB0FE7Q36237993-96979010-4168-4EC5-A791-741A026B7772Q36250461-F4CEC101-4F1C-42BE-85AA-A387F1F5CB83Q36290663-E2FDBA9D-0203-484C-BE97-99AE2E62D678Q36362961-C08349A0-9052-4493-83A7-BDAD532294CD
P2860
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Wild-type MIC distributions, e ...... T broth microdilution methods.
@ast
Wild-type MIC distributions, e ...... T broth microdilution methods.
@en
type
label
Wild-type MIC distributions, e ...... T broth microdilution methods.
@ast
Wild-type MIC distributions, e ...... T broth microdilution methods.
@en
prefLabel
Wild-type MIC distributions, e ...... T broth microdilution methods.
@ast
Wild-type MIC distributions, e ...... T broth microdilution methods.
@en
P2093
P1476
Wild-type MIC distributions, e ...... T broth microdilution methods.
@en
P2093
A Espinel-Ingroff
CLSI Subcommittee for Antifungal Susceptibility Testing
D J Diekema
M A Pfaller
P304
P356
10.1016/J.DRUP.2010.09.002
P577
2010-11-02T00:00:00Z